| 晚期非小细胞肺癌表皮生长因子受体-酪酸激酶抑制剂靶向治疗进展 |
| |
| 引用本文： | 洪群英,白春学. 晚期非小细胞肺癌表皮生长因子受体-酪酸激酶抑制剂靶向治疗进展[J]. 世界临床药物, 2012, 33(4): 197-201,210 |
| |
| 作者姓名： | 洪群英 白春学 |
| |
| 作者单位： | 洪群英 (复旦大学附属中山医院呼吸科,上海,200032) ； 白春学 (复旦大学附属中山医院呼吸科,上海,200032) ； |
| |
| 摘 要： | 随着分子生物学研究的深入,靶向治疗特别是表皮生长因子-酪氨酸激酶抑制剂(EGFR-TKI)为肺癌治疗开辟了蹊径。EGFR-TKI无论作为一线还是二、三线治疗或维持治疗对晚期非小细胞肺癌(NSCLC)均有效。本文概述EGFR-TKI在晚期NSCLC治疗中的应用进展。
|
| 关 键 词： | 非小细胞肺癌 靶向治疗 表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI) |
Progress of molecular-targeted therapy of EGFR-TKIs for advanced non-small cell lung cancer |
| |
| HONG Qun-ying,BAI Chun-xue. Progress of molecular-targeted therapy of EGFR-TKIs for advanced non-small cell lung cancer[J]. WORLD CLINICAL DRUGS, 2012, 33(4): 197-201,210 |
| |
| Authors: | HONG Qun-ying BAI Chun-xue |
| |
| Affiliation: | (Department of Respiratory,Zhongshan Hospital,Fudan University,Shanghai 200032,China) |
| |
| Abstract: | With the progress of molecular biology,targeted therapy especially epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs) become an important approach in the treatment of lung cancer.EGFR-TKIs are effective in either first,second and third-line treatment and maintenance therapy for advanced non-small cell lung cancer(NSCLC).This review describes progress of molecular-targeted therapy of EGFR-TKIs for advanced NSCLC. |
| |
| Keywords: | non-small cell cancer targeted therapy epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) |
| 本文献已被 CNKI 等数据库收录！ |
